Lantern Pharma Reports Significant Q2 2025 Achievements and Expands AI Platform

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has reported its Q2 2025 results, showcasing significant progress in its oncology drug development pipeline and the expansion of its AI platform, RADR(R). The company announced complete responses in patients across two clinical trials: LP-300 for advanced non-small cell lung cancer (NSCLC) and LP-284 for refractory diffuse large B-cell lymphoma. Additionally, Lantern Pharma has completed the Phase 1a enrollment for LP-184, setting the stage for Phase 1b/2 studies in high-value indications. LP-184, which has received FDA Fast Track and multiple Rare Pediatric Disease designations, demonstrated notable survival benefits in atypical teratoid rhabdoid tumor (ATRT) models.

The company also highlighted the strengthening of its intellectual property portfolio with a European patent allowance for LP-284 and the publication of a PCT application for its predictBBB(TM) AI module. Enhancements to the RADR(R) platform include the public launch of predictBBB.ai(TM) and the introduction of a new drug combination prediction module. Financially, Lantern Pharma reported a reduction in Q2 R&D expenses to $3.1 million from $3.9 million year-over-year, with G&A expenses slightly increasing to $1.6 million from $1.5 million. The net loss narrowed to $4.33 million from $4.96 million, and the company ended the quarter with $15.9 million in cash, equivalents, and marketable securities, ensuring funding for operations into June 2026.

For more details on Lantern Pharma's Q2 2025 results and portfolio updates, visit https://ibn.fm/VD5Ik. The advancements in Lantern Pharma's drug candidates and AI platform underscore the company's commitment to revolutionizing oncology drug discovery and development, offering hope for more effective and efficient cancer treatments.